Opinions

Recent evidence shows the potential of immunotherapy to change the treatment landscape of triple-negative breast cancer (TNBC), where historically, chemotherapy has been the only systemic option. But, how do we choose what therapy to give which patients?

After TILs have shown benefits in advanced melanoma, many ‘synthetic biology’ strategies can be conceived to potentially extend this clinical signal to other patient groups

The availability and affordability of a broad range of prescription cancer medicines have been analysed

In the post-COVID-19 era, there is a need to evaluate the quality, safety and effectiveness of telehealth to deliver cancer care says ESMO Keynote Lecturer Dr Deborah Schrag   

Oncologists at an early stage in their career may fall into the trap of predatory journals whilst seeking to publish their research 

In the Patient Advocacy Track, the importance and challenges around placing the patient at the centre of clinical trials 

The advent of PARP inhibitors, an increased use of laparoscopy for patient selection and a more prominent role of PROs have been facilitated by international collaborations

Will widespread screening for breast cancer based on individual risk mean the end of the one-size-fits-all standard mammogram?

Gene-expression assays have produced a huge step forward in identifying patients who are likely to benefit from adjuvant chemotherapy but there is still a long way to go in the more specific targeting of treatment

Much progress has been made in the standardisation of pathological response but optimising viable tumour cutoffs for predicting long-term outcome after different treatment modalities and by histological type remain key areas for investigation